Skip to main content

ORIGINAL RESEARCH article

Front. Med.
Sec. Gastroenterology
Volume 11 - 2024 | doi: 10.3389/fmed.2024.1510376

Effect of an individualized bismuth quadruple regimen guided by 10day or 14-day antibiotic susceptibility testing for first-line eradication treatment of Helicobacter pylori in Ningxia, China

Provisionally accepted
Xiaoming Su Xiaoming Su 1*Yanhong Deng Yanhong Deng 2Xianmei Chen Xianmei Chen 2Yanling Li Yanling Li 2Qian Hao Qian Hao 2Yuanyuan Tang Yuanyuan Tang 2Rui Mu Rui Mu 2Yuting Wu Yuting Wu 2Yan Zhou Yan Zhou 3Shengjuan Hu Shengjuan Hu 2*
  • 1 The Fifth People's Hospital of Ningxia Hui Autonomous Region, Shizuishan, Ningxia, China, Ningxia Hui Autonomous Region People's Hospital, Yinchuan, China
  • 2 Ningxia Hui Autonomous Region People's Hospital, Yinchuan, China
  • 3 General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Region, China

The final, formatted version of the article will be published soon.

    Helicobacter pylori (H. pylori) is becoming more resistant to antibiotics, and the implementation of individualized therapy is highly valuable for its eradication. This study aimed to investigate the efficacy and safety of individualized treatment guided by antibiotic susceptibility testing (AST) with a 10-day or 14-day course for the eradication of H. pylori.Methods: This was a prospective, open-label, single-center, quasi-randomized trial in which 220 participants were randomized into groups based on AST results as AST-10-day (n = 98) and AST-14day (n = 112) treatment groups. All participants were retested for a 14-carbon urease breath test at weeks 4-8 after the end of the treatment.Results: The primary resistance rates of H. pylori to metronidazole, levofloxacin, clarithromycin, and amoxicillin were 94.1% (207/220), 42.7% (95/220), 41.4% (91/220), and 0.9% (2/220), respectively; however, no resistance to furazolidone and tetracycline was observed. In the AST-10day and AST-14-day groups, the intention-to-treat (ITT) eradication rates were 89.8% (88/98) and 90.2% (110/122), respectively, with no statistically significant difference (P = 0.928). The per- protocol (PP) eradication rates were 92.6% (88/95) and 98.2% (110/112), respectively, with a statistically significant difference (P = 0.049). The incidence rates of adverse events (AEs) in the AST-10-day and AST-14-day groups were 6.3% (6/95) and 7.2% (8/112), respectively, with no statistically significant difference (P = 0.813). No statistically significant difference was observed in compliance between the two groups (P = 0.467).Conclusions: Both 10-day and 14-day AST guided individualized therapy can achieve satisfactory eradication effect. Compared with the 14-day regimen, the 10-day regimen has similar eradication rate and incidence of adverse events and compliance but shorter duration and lower cost.

    Keywords: Helicobacter pylori, individualized therapy, Antibiotic Sensitivity Test, adverse events, Eradication rate

    Received: 12 Oct 2024; Accepted: 23 Dec 2024.

    Copyright: © 2024 Su, Deng, Chen, Li, Hao, Tang, Mu, Wu, Zhou and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Xiaoming Su, The Fifth People's Hospital of Ningxia Hui Autonomous Region, Shizuishan, Ningxia, China, Ningxia Hui Autonomous Region People's Hospital, Yinchuan, China
    Shengjuan Hu, Ningxia Hui Autonomous Region People's Hospital, Yinchuan, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.